Links to medical information on PID
The Immune Deficiency Foundation (IDF) is the national (USA) non-profit health organization dedicated to improving the diagnosis and treatment of primary immune deficiency diseases through research and education. IDF is governed by a Board of Trustees, has an active Medical Advisory Committe comprised of prominent clinical immunologists, a nationwide volunteer support network, and a dedicated professional staff.
The Working Group Pediatric Immunology (API) consists of doctors and scientists from Germany, Austria and Switzerland. They are all occupied witrh research and treatment of PIDs in chsildren and young adults.
This website serves as an information-page for patients and their families and general practitioners (GPs) and is directed towards the German speaking audience.
(Language in the website is German)
Die API ist eine Arbeitsgemeinschaft von Ärzten und Wissenschaftlern aus Deutschland, Österreich und der Schweiz, die sich mit der Erkennung, Erforschung und Behandlung von Erkrankungen des Immunsystems bei Kindern und Jugendlichen beschäftigen.
Diese Homepage soll betroffenen Patienten und ihren Familien sowie interessierten Ärzten als Orientierung dienen, um sich über immunologische Erkrankungen und die Versorgungsmöglichkeiten im deutschen Sprachraum zu informieren.
The European Society for Immunodeficiencies (ESID) is a non-profit organization having multiple aims. The main objectives are to facilitate the exchange of ideas and information among doctors, nurses, biomedical investigators, patients and their families concerned with primary immunodeficiency diseases and also to promote research on causes, mechanisms and treatment of these disorders. Recently ESID has initiated an educational program.
Aside from fundraising to support medical research, the charity also has two other key functions:
Immunoglobulin Supply and Safety
It is important that primary immunodeficiencies are recognised as a public health issue so that there is greater awareness of the causes of the presenting symptoms and thereby diagnosis of the underlying conditions rather than the simple treatment of the symptoms themselves. Precocious treatment (there is no prevention of the disease up to now!! ) of primary immunodeficiencies will – in the long run – save huge costs for the society.
Several therapies are available for the treatment of primary immunodeficiencies. The vast majority of diagnosed conditions are treatable with blood products – especially immunoglobulins or C1-INH. It should be noted that those therapies neither cure the conditions nor do they reverse all the damage brought about by late diagnosis.
The blood product market place has been fraught with problems in the past. For example transmission of hepatitis C in some batches of immunglobulin ans HIV in blood products for haemophiliacs – but there has been no recent history of such problems due to the exhaustive viral control measures implemented during the manufacturing process of plasma derivatives.
The efficient removal of prions (responsible for vCJD) during the manufacturing processes of plasma derivatives has been well documented and measures have been taken to avoid using plasma from donors in areas of high risk.
This elimination of pathogens in immunglobulins is based on three principles:
The market is vulnerable, however, and the need to achieve a balanced supply of product to meet growing demand can lead to acute product shortages and at times this can be a risk for primary immunodeficient patients.
It has to be appreciated that the costs involved in meeting the high standards in plasma collection and manufacturing, to ensure safe end products, are high but in the interests of the public health. Standards are demanded by regulatory authorities as well as industry itself.
It is also salutary to note that the blood product industry is the only industry that relies on the human body for its source product – i.e. human plasma – as opposed to raw non-human chemical materials.
Travel With PID (for internationals)
1. Recommendations - in general
2. Proposal On "Letter To Customs Officials"
To Customs in: (Port of Entry)
A person with primary immunodeficiency protects their health by taking regular infusions of immunoglobulin. This preparation is based on human plasma.
___________________ (patient’s name) who suffers from a primary immunodeficiency is traveling to ________________________. It would not be possible for ________________________ (patient's name) to travel without a supply of immunoglobulin. He/she carries sufficient units for maintenance therapy and additional amounts in the event of an emergency.
A customs official who inadvertently withholds the bottles of human plasma immunoglobulin may place _____________________ (patient's name) life in jeopardy. For the purposes of comparison it would be as if insulin were withheld from a diabetic.
In anticipation of your co-operation, I am
3. Proposal On Travel Letter To Doctors
To Whom It May Concern
Name of patient: _____________________________________
This patient has a primary immunodeficiency and is well know to me. In order to stay well or overcome severe infections immunoglobulins have to be infused.
Carries a supply of this medication and will know when and under what circumstances an infusion should take place.